Clinical performance of titanium-zirconium implants with a hydrophilic surface in patients with controlled type 2 diabetes mellitus: 2-year results from a prospective case-control clinical study
| Autor: | Guillermo Machuca-Portillo, José Cabrera-Domínguez, Manuel Pérez-Fierro, Daniel Torres-Lagares, Lizett Castellanos-Cosano |
|---|---|
| Přispěvatelé: | Institut Straumann |
| Rok vydání: | 2020 |
| Předmět: |
endocrine system diseases
Bleeding on probing Dentistry 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Glycated hemoglobin a Type 2 diabetes mellitus medicine Humans In patient Prospective Studies TiZr alloy General Dentistry Hydrophilicity Dental Implants Titanium business.industry Dental implants Clinical performance Type 2 Diabetes Mellitus nutritional and metabolic diseases 030206 dentistry Titanium zirconium chemistry Dental Prosthesis Design Diabetes Mellitus Type 2 030220 oncology & carcinogenesis Implant Glycated hemoglobin Zirconium medicine.symptom business |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| Popis: | [Objective[: Analyze the 2-year clinical performance of single-unit titanium-zirconium (TiZr) alloy narrow-diameter (3.3 mm) dental implants with a hydrophilic surface (Straumann® Roxolid®, SLActive®) in patients with controlled type 2 diabetes mellitus (T2DM), measured using the glycated hemoglobin A (HbA1c) concentration test, compared with results in individuals without T2DM. [Material and methods]: The studied sample consisted of 28 patients, 14 with T2DM (study group) and 14 without (control group). The plaque index, bleeding on probing, probing depth, clinical attachment level, gingival biotype, and marginal bone loss (MBL) at the site of the implants were assessed. HbA1c levels were assessed in all patients during each checkup. [Results]: Two years after implant placement and prosthetic restoration no implant failures were reported in either group, resulting in 100% survival and success rates in both groups. No statistically significant differences in MBL were found between the control and study groups (p > 0.05). [Conclusions]: Within the limitations of this study, it can be concluded that reduced-diameter TiZr alloy implants with a hydrophilic surface represent a safe and predictable treatment option for patients with well-controlled T2DM. The clinical performance was comparable with that observed in individuals without T2DM in the medium term. [Clinical relevance]: The narrow implants placed in patients with T2DM with well-controlled glycemia (HbA1c) showed a marginal bone loss and success and survival rates similar to those of the control group without DM2, in the medium term. This study was funded by Institut Straumann AG Peter Merian-Weg 12, CH-4002 Basel (Switzerland) (research grant number IIS 18/10). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|